Steven Kanner
Direttore Tecnico/Scientifico/R&S presso CARIBOU BIOSCIENCES, INC.
Patrimonio netto: 1 M $ in data 30/04/2024
Posizioni attive di Steven Kanner
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2017 | - |
Specific Biologics, Inc.
 Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Direttore/Membro del Consiglio | 10/10/2023 | - |
| Independent Dir/Board Member | 10/10/2023 | - |
Storia della carriera di Steven Kanner
Precedenti posizioni note di Steven Kanner
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19/09/2013 | 01/06/2017 |
Formazione di Steven Kanner
| University of California, Berkeley | Undergraduate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Canada | 2 |
Posizioni
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Specific Biologics, Inc.
Specific Biologics, Inc. Miscellaneous Commercial ServicesCommercial Services Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead. | Commercial Services |
- Borsa valori
- Insiders
- Steven Kanner
- Esperienza
